Seer Net Income 2021-2021 | SEER

Seer net income from 2021 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Seer Annual Net Income
(Millions of US $)
2021 $-71
2020 $-33
Seer Quarterly Net Income
(Millions of US $)
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.536B $0.007B
Seer Inc. is a life sciences company. It engages in developing Proteograph(TM), which is an integrated solution consisting of consumables, automation instrumentation and proprietary software. Seer Inc. is based in REDWOOD CITY, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.746B 9.96
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.525B 16.61
Biohaven Pharmaceutical Holding (BHVN) United States $9.916B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.438B 6.15
Arcus Biosciences (RCUS) United States $1.419B 35.98
Myovant Sciences (MYOV) United Kingdom $0.944B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.492B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.309B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.085B 0.00